# Pfizer Inc: Form 10-Q for the period ended Sep 27, 2020

- Company: [Pfizer Inc](/companies/pfe.md) (CIK 78003)
- Form: 10-Q
- Filed: 2020-11-05
- Accepted by EDGAR: Nov 5, 2020, 21:57 ET
- Period: 2020-09-27
- Accession: 0000078003-20-000070
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/78003/000007800320000070/pfe-20200927.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/78003/000007800320000070/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-09-27.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-06-29 to 2020-09-27 | $12.13bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2020-01-01 to 2020-09-27 | $35.96bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2020-06-29 to 2020-09-27 | $2.53bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2020-01-01 to 2020-09-27 | $7.19bn | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months, 2020-06-29 to 2020-09-27 | $3.02bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2020-01-01 to 2020-09-27 | $8.92bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months, 2020-06-29 to 2020-09-27 | $416.0m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2020-01-01 to 2020-09-27 | $1.18bn | us-gaap:InterestExpense |
| Income tax | 3 months, 2020-06-29 to 2020-09-27 | −$26.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2020-01-01 to 2020-09-27 | $968.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-06-29 to 2020-09-27 | $2.19bn | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2020-01-01 to 2020-09-27 | $9.02bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-06-29 to 2020-09-27 | $0.39 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2020-01-01 to 2020-09-27 | $1.60 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2020-06-29 to 2020-09-27 | $0.39 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2020-01-01 to 2020-09-27 | $1.62 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2020-06-29 to 2020-09-27 | 5,633,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2020-01-01 to 2020-09-27 | 5,622,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2020-01-01 to 2020-09-27 | $8.78bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2020-01-01 to 2020-09-27 | $1.47bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months, 2020-01-01 to 2020-09-27 | $0 | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2020-09-27 | $1.59bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-09-27 | $47.74bn | us-gaap:AssetsCurrent |
| Total assets | at 2020-09-27 | $178.98bn | us-gaap:Assets |
| Current liabilities | at 2020-09-27 | $34.15bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-09-27 | $113.49bn | us-gaap:Liabilities |
| Long-term debt | at 2020-09-27 | $49.78bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2020-09-27 | $2.15bn | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2020-09-27 | $10.99bn | us-gaap:CommercialPaper |
| Shareholders' equity | at 2020-09-27 | $65.26bn | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/78003/000007800320000070/pfe-20200927.htm

Filed Nov 5, 2020.
Source: SEC EDGAR, the filing index for accession 0000078003-20-000070. Last ingested by Listed: Nov 12, 2026, 18:08 ET. No prices; not investment advice.
